vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and New Fortress Energy Inc. (NFE). Click either name above to swap in a different company.
New Fortress Energy Inc. is the larger business by last-quarter revenue ($326.2M vs $191.2M, roughly 1.7× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -7.0%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -26.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
New Fortress Energy Inc. is a global energy infrastructure firm developing, owning and operating LNG import/export terminals, natural gas supply networks and low-carbon projects. It serves utility, industrial and public sector clients across the Americas and Caribbean, delivering affordable, lower-emission energy resources.
AXSM vs NFE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $326.2M |
| Net Profit | — | $-847.1M |
| Gross Margin | — | 35.5% |
| Operating Margin | -33.1% | -193.0% |
| Net Margin | — | -259.7% |
| Revenue YoY | 57.4% | -7.0% |
| Net Profit YoY | — | -277.4% |
| EPS (diluted) | — | $-3.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $326.2M | ||
| Q3 25 | $171.0M | $240.3M | ||
| Q2 25 | $150.0M | $228.1M | ||
| Q1 25 | $121.5M | $384.9M | ||
| Q4 24 | $118.8M | $350.7M | ||
| Q3 24 | $104.8M | $446.0M | ||
| Q2 24 | $87.2M | $291.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-847.1M | ||
| Q3 25 | $-47.2M | $-263.0M | ||
| Q2 25 | $-48.0M | $-546.5M | ||
| Q1 25 | $-59.4M | $-175.4M | ||
| Q4 24 | $-74.9M | $-224.4M | ||
| Q3 24 | $-64.6M | $9.3M | ||
| Q2 24 | $-79.3M | $-88.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 35.5% | ||
| Q3 25 | — | 18.1% | ||
| Q2 25 | — | 8.4% | ||
| Q1 25 | — | 21.4% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | — | 27.1% | ||
| Q2 24 | — | 23.8% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -193.0% | ||
| Q3 25 | -27.0% | -37.4% | ||
| Q2 25 | -24.5% | -170.3% | ||
| Q1 25 | -46.9% | -3.3% | ||
| Q4 24 | -61.1% | 65.0% | ||
| Q3 24 | -59.8% | 17.8% | ||
| Q2 24 | -89.5% | 12.3% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -259.7% | ||
| Q3 25 | -27.6% | -109.4% | ||
| Q2 25 | -32.0% | -239.6% | ||
| Q1 25 | -48.9% | -45.6% | ||
| Q4 24 | -63.1% | -64.0% | ||
| Q3 24 | -61.7% | 2.1% | ||
| Q2 24 | -91.0% | -30.5% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-3.03 | ||
| Q3 25 | $-0.94 | $-0.96 | ||
| Q2 25 | $-0.97 | $-1.99 | ||
| Q1 25 | $-1.22 | $-0.65 | ||
| Q4 24 | $-1.54 | $-1.10 | ||
| Q3 24 | $-1.34 | $0.03 | ||
| Q2 24 | $-1.67 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $226.5M |
| Total DebtLower is stronger | $70.0M | $8.2B |
| Stockholders' EquityBook value | — | $182.6M |
| Total Assets | $713.6M | $10.6B |
| Debt / EquityLower = less leverage | — | 44.78× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $226.5M | ||
| Q3 25 | $325.3M | $145.2M | ||
| Q2 25 | $303.0M | $551.1M | ||
| Q1 25 | $300.9M | $447.9M | ||
| Q4 24 | $315.4M | $492.9M | ||
| Q3 24 | $327.3M | $90.8M | ||
| Q2 24 | $315.7M | $133.0M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $8.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $182.6M | ||
| Q3 25 | $73.7M | $1.1B | ||
| Q2 25 | $73.1M | $1.3B | ||
| Q1 25 | $53.2M | $1.8B | ||
| Q4 24 | $57.0M | $1.9B | ||
| Q3 24 | $92.9M | $1.6B | ||
| Q2 24 | $102.9M | $1.6B |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $10.6B | ||
| Q3 25 | $669.3M | $12.0B | ||
| Q2 25 | $639.8M | $12.0B | ||
| Q1 25 | $596.7M | $13.1B | ||
| Q4 24 | $568.5M | $12.9B | ||
| Q3 24 | $561.5M | $12.0B | ||
| Q2 24 | $548.2M | $11.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 44.78× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.74× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-76.2M |
| Free Cash FlowOCF − Capex | — | $-134.8M |
| FCF MarginFCF / Revenue | — | -41.3% |
| Capex IntensityCapex / Revenue | — | 18.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-76.2M | ||
| Q3 25 | $1.0M | $-171.0M | ||
| Q2 25 | $-32.4M | $-329.0M | ||
| Q1 25 | $-43.4M | $-7.2M | ||
| Q4 24 | $-26.2M | $445.3M | ||
| Q3 24 | $-18.6M | $-20.0M | ||
| Q2 24 | $-30.1M | $113.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-134.8M | ||
| Q3 25 | $988.0K | $-231.6M | ||
| Q2 25 | $-32.4M | $-726.7M | ||
| Q1 25 | $-43.7M | $-262.3M | ||
| Q4 24 | $-26.2M | $-210.3M | ||
| Q3 24 | $-18.7M | $-367.0M | ||
| Q2 24 | $-30.2M | $-493.2M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | -41.3% | ||
| Q3 25 | 0.6% | -96.4% | ||
| Q2 25 | -21.6% | -318.6% | ||
| Q1 25 | -36.0% | -68.2% | ||
| Q4 24 | -22.1% | -60.0% | ||
| Q3 24 | -17.9% | -82.3% | ||
| Q2 24 | -34.6% | -169.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 18.0% | ||
| Q3 25 | 0.0% | 25.2% | ||
| Q2 25 | 0.0% | 174.4% | ||
| Q1 25 | 0.3% | 66.3% | ||
| Q4 24 | 0.0% | 187.0% | ||
| Q3 24 | 0.1% | 77.8% | ||
| Q2 24 | 0.1% | 208.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -2.15× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
NFE
Segment breakdown not available.
